Plaintiff
2 cases as plaintiff.
Otsuka Pharmaceutical Co., Ltd. (OPC), often abbreviated as Otsuka Pharmaceutical, is a global healthcare company headquartered in Chiyoda, Tokyo, Japan. It was established on August 10, 1964, and operates as a core subsidiary of Otsuka Holdings Co., Ltd., which was founded in 1921. Otsuka Holdings is publicly traded on the Tokyo Stock Exchange (TSE: 4578). As of fiscal year 2025, Otsuka Holdings reported consolidated revenue of ¥2,468.9 billion (approximately $15.6 billion USD) and employs approximately 37,758 people globally across 182 group companies.
Otsuka Pharmaceutical operates in two primary business segments: pharmaceuticals and nutraceuticals. In the pharmaceutical sector, Otsuka is a global leader in Central Nervous System (CNS) disorders, nephrology, and oncology, known for developing treatments such as Abilify (aripiprazole) and Rexulti (brexpiprazole). Their nutraceutical business offers science-based products for maintaining and improving health, including popular brands like POCARI SWEAT, Calorie Mate, and Nature Made vitamins.
Otsuka Pharmaceutical consistently acts as a plaintiff in patent litigation, with all three of its tracked cases appearing in the U.S. District Court for the District of Delaware. This indicates an active posture in defending its intellectual property, particularly related to its pharmaceutical products. The cases, filed in 2013 and 2014, generally involve Otsuka Pharmaceutical Co., Ltd. asserting its patents against other pharmaceutical companies, such as Hetero USA Inc., Par Pharmaceutical Inc., and Lupin Ltd. These lawsuits are typical of Hatch-Waxman litigation, where a brand-name pharmaceutical company defends its drug patents against generic manufacturers seeking to market generic versions.
Notable cases include Otsuka Pharmaceutical Co., Ltd. v. Hetero USA Inc. et al. and Otsuka Pharmaceutical Co. Ltd. v. Par Pharmaceutical Inc., both concerning patent infringement. These cases often revolve around patents protecting key drugs like aripiprazole, the active ingredient in Abilify. Otsuka's litigation strategy aims to protect its market exclusivity and prevent the entry of generic competition, frequently challenging generic manufacturers' Abbreviated New Drug Applications (ANDAs).
Watchlist
Email-only, free, anonymous. We'll notify you when Otsuka Pharmaceutical Co., Ltd. files another patent-infringement lawsuit. One-click unsubscribe from any alert.
Otsuka Pharmaceutical Co., Ltd. filed suit against Hetero USA Inc., Hetero Labs Ltd. Unit V, and Hetero Labs Limited in the District of Delaware regarding US Patent 8501730. The outcome of the case is not detailed.
The District Court found Lupin did not infringe US Patent 8501730 and US Patent 8273735, with US Patent 8273735 also found invalid as obvious. On appeal, the Federal Circuit affirmed the non-infringement finding for 8501730, but controversially determined its asserted method claims were invalid as obvious.